#Paris #France #Heart Valve #Venus Medtech #Cardiovalve

Venus Medtech's Inaugural Global Partner Summit in Paris

In a landmark event, Venus Medtech convened its first Global Partner Summit in Paris, themed "Insights, Innovation, Impact." This gathering brought together distributors and commercial partners to discuss the company's strategic approach to international growth, the expansion of its structural heart portfolio, and long-term commercialization priorities. The summit marked a significant step in Venus Medtech's ongoing commitment to strengthen relationships with its global partner network and enhance its position in international markets.

The event commenced with remarks from David Bréant, the Vice President of Sales and Marketing at Venus Medtech. He emphasized the company’s remarkable journey from being an emerging innovator to establishing itself as a significant player in the global structural heart market. Bréant underlined the importance of clinical collaboration, product quality, and consistent execution as crucial elements of the company’s evolution.

Hou-Sen Lim, the General Manager and CEO, provided a detailed overview of the company’s strategic roadmap. He highlighted the progress made with the transcatheter valve portfolio and discussed upcoming regulatory and commercial milestones. Lim explained that Venus Medtech is transitioning from a product-centric organization to a comprehensive structural heart company that offers multiple valve therapies. This transition highlights the company’s commitment to addressing a broader range of heart conditions and patient needs.

A key session was led by Professor Francesco Maisano, a prominent figure in cardiac surgery who serves as the Director of the Valve Clinic at IRCCS San Raffaele University Hospital. His presentation focused on the development of the Cardiovalve system, which addresses the increasing demand for transcatheter treatment options for mitral regurgitation (MR) and tricuspid regurgitation (TR). During his talk, Maisano highlighted several innovative design features of the Cardiovalve system, including:

• - Single-step transfemoral access: Streamlining the procedure for greater efficiency.
• - Unified platform for both mitral and tricuspid procedures: Allowing for versatile use in various procedures.
• - Low-profile design: Reducing the risk of left ventricular outflow tract (LVOT) obstruction.
• - Adaptive sealing mechanism: Minimizing the occurrence of paravalvular leak (PVL), a common complication in valve procedures.

Professor Maisano noted that the current device sizing is designed to accommodate approximately 85% of the target patient population, showcasing the company’s focus on accessibility and patient-centered care. Additionally, the session shed light on the tricuspid valve, often referred to as the “forgotten valve,” due to historically limited treatment options. The increasing clinical and commercial interest in therapies for this valve signifies a pivotal shift in the market landscape.

In conclusion, Hou-Sen Lim reiterated that international expansion remains a core strategic priority for Venus Medtech. Following the successful launch of the Venus P-Valve in international markets, the company is actively working on advancing clinical, regulatory, and commercialization pathways for innovative products such as Venus-PowerX, Venus-Vitae, and Cardiovalve. Lim affirmed their commitment to building long-term clinical credibility while enhancing their presence in the global structural heart market through a diversified product portfolio.

To support this growth, Venus Medtech continues to invest in local commercial capabilities, infrastructure, and market-specific expertise, laying the groundwork for sustained international success.

About Venus Medtech

Venus Medtech (Hangzhou) Inc. (2500.HK) specializes in the development of transcatheter heart valve technologies and treatment solutions for various structural heart diseases. The company’s pipeline includes a range of products for transcatheter aortic, pulmonary, mitral, and tricuspid valve therapies, along with associated accessories. With research and development centers located in China, the United States, and Israel, Venus Medtech is poised for continued innovation in the medical device industry.